Contribution: Industrial Research Assistance Program – Contributions to Firms
Skinopathy Inc.
$30,000.00
TMU Growth Marketing Program
FY 2024-25 · 2024-10-01
Summary
The firm wishes to develop, implement and optimize a digital/growth marketing strategy to benefit the firm with its sales revenues, increase product awareness and reduce sales and marketing costs.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
North York|North York, Ontario, Canada
Recipient Type
For-profit organization
Business Number
716340872
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2024-10-01 | 2024-25 | $30,000.00 |
| 1 | 2024-10-01 | 2024-25 | $30,000.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 31 days.
Additional Information (French)
Cet accord a été modifié 1 fois La date de fin du présent accord a été changé de 31 jours.
Agreement End Date
2025-03-31
Agreement Number
1022871
Agreement Start Date
2024-10-01
Agreement Title
TMU Growth Marketing Program
Agreement Title (French)
Programme de marketing de croissance d’UMT
Agreement Type
Contribution
Agreement Value
$30,000.00
Amendment Date
2025-02-19
Amendment Number
1
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
The firm wishes to develop, implement and optimize a digital/growth marketing strategy to benefit the firm with its sales revenues, increase product awareness and reduce sales and marketing costs.
Description (French)
L’entreprise souhaite développer, mettre en œuvre et optimiser une stratégie de marketing numérique/de croissance afin de faire bénéficier l’entreprise de son chiffre d’affaires, d’accroître la notoriété des produits et de réduire les coûts de vente et de marketing.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Willowdale
Federal Riding (French)
Willowdale
Federal Riding Number
35115
NAICS Code
511211
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
716340872
Recipient City
North York|North York
Recipient Country
CA
Recipient Legal Name
Skinopathy Inc.
Recipient Operating Name
Skinopathy
Recipient Postal Code
M2N 1N5
Recipient Province or Territory
ON
Recipient Type
F
Reference Number
172-2024-2025-Q3-1022871
